

Marek Z Wojtukiewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6034661/publications.pdf>

Version: 2024-02-01

122
papers

5,048
citations

126708

33
h-index

95083

68
g-index

127
all docs

127
docs citations

127
times ranked

6167
citing authors

#	ARTICLE	IF	CITATIONS
1	Ozonation of Whole Blood Results in an Increased Release of Microparticles from Blood Cells. <i>Biomolecules</i> , 2022, 12, 164.	1.8	4
2	Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade. <i>Pathology and Oncology Research</i> , 2021, 27, 605017.	0.9	3
3	Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. <i>Biomolecules</i> , 2021, 11, 663.	1.8	8
4	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
5	Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions. <i>Cells</i> , 2021, 10, 2044.	1.8	14
6	Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm. <i>Cancers</i> , 2020, 12, 1144.	1.7	18
7	Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy. <i>Pathology and Oncology Research</i> , 2020, 26, 2499-2507.	0.9	13
8	Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. <i>In Vivo</i> , 2019, 33, 771-776.	0.6	6
9	It is not just the drugs that matter: the nocebo effect. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 315-326.	2.7	10
10	PET/MRI-guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 780-791.	1.0	33
11	Personalized Radiation Therapy in Cancer Pain Management. <i>Cancers</i> , 2019, 11, 390.	1.7	17
12	Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy. <i>In Vivo</i> , 2019, 33, 581-586.	0.6	0
13	Endothelial Microparticles and Blood Coagulation Activation in Head and Neck Cancer Patients Undergoing Radiotherapy or Radiochemotherapy. <i>In Vivo</i> , 2019, 33, 627-632.	0.6	3
14	Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination. <i>Cancers</i> , 2019, 11, 51.	1.7	20
15	Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (>=20%) FN-risk chemotherapy: results from a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 1449-1457.	1.0	7
16	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. <i>European Journal of Cancer</i> , 2018, 93, 19-27.	1.3	58
17	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 968-974.	0.8	78
18	EP-1179: Usefulness of [18F]FDG-PET/MRI in clinical evaluation of head and neck cancer (HNC) patients (pts). <i>Radiotherapy and Oncology</i> , 2018, 127, S660-S661.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
20	Thromboprophylaxis in cancer patients in hospice. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 283-289.	0.6	4
21	Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12631-e12631.	0.8	1
22	Is AIO belly board device advantageous in all rectal cancer patients. <i>Nowotwory</i> , 2018, 67, 342-348.	0.1	0
23	Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 305-329.	2.7	46
24	Platelets and cancer angiogenesis nexus. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 249-262.	2.7	172
25	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	0.8	11
26	Massive saddle pulmonary embolism during radiochemotherapy of head and neck cancer. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 561-563.	0.3	4
27	Polish Consensus on Treatment of Gastric Cancer; update 2017. <i>Polski Przegląd Chirurgiczny</i> , 2017, 89, 59-73.	0.2	2
28	Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?. <i>Wspolczesna Onkologia</i> , 2016, 2, 102-108.	0.7	6
29	Thrombinâ€”unique coagulation system protein with multifaceted impacts on cancer and metastasis. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 213-233.	2.7	68
30	Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 455-457.	0.4	5
31	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	5.1	125
32	Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 505-511.	0.6	10
33	Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 1185-1192.	0.6	2
34	Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients. <i>Nowotwory</i> , 2016, 66, 326-350.	0.1	2
35	Protease-activated receptors â€” biology and role in cancer. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 775-786.	0.1	5
36	Wyniki leczenia wemurafenibem chorych na zaawansowanego czerniaka w ramach programu lekowego w Polsce. <i>Nowotwory</i> , 2016, 66, 118-126.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Hippocampal sparing in brain radiotherapy. <i>Nowotwory</i> , 2016, 66, 299-306.	0.1	1
38	Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience. <i>International Dental Journal</i> , 2015, 65, 242-248.	1.0	17
39	Protease-activated receptors (PARs) – biology and role in cancer invasion and metastasis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 775-796.	2.7	109
40	Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1. <i>Cancer Research</i> , 2015, 75, P5-19-01-P5-19-01.	0.4	8
41	Wszczipalne systemy dostępu naczyniowego u chorych na nowotwory. <i>Nowotwory</i> , 2015, 65, 302-316.	0.1	0
42	Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 1426-31.	0.4	3
43	Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. <i>Wspolczesna Onkologia</i> , 2014, 6, 419-424.	0.7	0
44	Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project. <i>Wspolczesna Onkologia</i> , 2014, 6, 425-428.	0.7	2
45	Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer. <i>Annals of Hematology</i> , 2014, 93, 779-784.	0.8	13
46	Testicular Dose Contributed by Image-Guided Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S426.	0.4	0
47	Testicular Doses in Image Guided Step-and-Shoot Intensity Modulated Radiation Therapy of Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S377.	0.4	0
48	Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. <i>Advances in Medical Sciences</i> , 2013, 58, 207-215.	0.9	16
49	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. <i>Wspolczesna Onkologia</i> , 2013, 3, 257-262.	0.7	11
50	Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue. <i>Thrombosis Research</i> , 2012, 129, e92-e96.	0.8	14
51	Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: Implications for coagulation regulation on tumor cells. <i>Thrombosis Research</i> , 2012, 129, e112-e118.	0.8	25
52	Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1055-1062.	5.1	101
53	Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment*. , 2012, , .		1
54	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	0.8	11

#	ARTICLE	IF	CITATIONS
55	7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC). <i>European Journal of Cancer</i> , 2011, 47, S517.	1.3	7
56	882 poster 3-YEAR OVERALL SURVIVAL FOR INOPERABLE NON-SMALL CELL LUNG CARCINOMA PATIENTS TREATED WITH RA-DIOCHEMOTHERAPY â€“ SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.. <i>Radiotherapy and Oncology</i> , 2011, 99, S340.	0.3	0
57	924 poster ADIUVANT RADIOCHEMOTHERAPY FOR GASTRIC CANCER PATIENTS â€“ SINGLE-INSTITUTION RETROSPECTIVE EXPERIENCE.. <i>Radiotherapy and Oncology</i> , 2011, 99, S355.	0.3	0
58	Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. <i>Onkologie</i> , 2011, 34, 233-238.	1.1	8
59	Psychological, Physical, and Social Situation of Polish Patients With Colorectal Cancer Undergoing First-Line Palliative Chemotherapy. <i>Oncology Nursing Forum</i> , 2011, 38, E253-E259.	0.5	2
60	Protein Z is present in human breast cancer tissue. <i>International Journal of Hematology</i> , 2011, 93, 681-683.	0.7	15
61	Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. <i>Tumor Biology</i> , 2011, 32, 753-759.	0.8	11
62	Cancer epidemiology in Central and South Eastern European countries. <i>Croatian Medical Journal</i> , 2011, 52, 478-487.	0.2	53
63	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011, 31, 843-7.	0.5	5
64	Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. <i>Thrombosis and Haemostasis</i> , 2010, 104, 183-185.	1.8	15
65	Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. <i>Thrombosis and Haemostasis</i> , 2010, 103, 198-204.	1.8	41
66	Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. <i>Thrombosis Research</i> , 2010, 125, e71-e75.	0.8	17
67	Increased serum level of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) in patients with breast cancer.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 48, 101-3.	0.6	20
68	Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Annals of Oncology</i> , 2009, 20, 1794-1802.	0.6	63
69	The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. <i>International Journal of Hematology</i> , 2009, 89, 276-284.	0.7	2
70	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	0.6	247
71	The Role of Tissue Factor Pathway Inhibitor-2 in Cancer Biology. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 653-659.	1.5	86
72	Inhibitors of Hemostatic System in Cancer: Basic and Clinical Aspects. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 619-620.	1.5	1

#	ARTICLE	IF	CITATIONS
73	The Role of Hemostatic System Inhibitors in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 621-642.	1.5	27
74	Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 712-721.	1.5	108
75	PO-28 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes. <i>Thrombosis Research</i> , 2007, 120, S154.	0.8	2
76	Comparative Analysis of Coagulation System Proteins Distribution in Breast Cancer Primary Lesions and Lymph Node Metastases.. <i>Blood</i> , 2007, 110, 3137-3137.	0.6	0
77	The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. <i>Clinica Chimica Acta</i> , 2006, 371, 112-116.	0.5	23
78	Enhanced prolidase activity and decreased collagen content in breast cancer tissue. <i>International Journal of Experimental Pathology</i> , 2006, 87, 289-296.	0.6	60
79	Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. <i>British Journal of Cancer</i> , 2006, 95, 788-793.	2.9	52
80	Heterogeneous Expression of Protein C (PC), Protein S (PS) and Thrombomodulin (TM) in Human Colon Cancer Tissue.. <i>Blood</i> , 2006, 108, 4037-4037.	0.6	1
81	TFPI (Tissue Factor Pathway Inhibitor) Is Present in Breast Cancer Tumor Cells.. <i>Blood</i> , 2006, 108, 4035-4035.	0.6	6
82	Cancer procoagulant in patients with adenocarcinomas. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 543-547.	0.5	19
83	First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 1178-1184.	0.8	444
84	Evaluation of Urokinase-Type Plasminogen Activator and Its Receptor in Neointima of Polyester Vascular Grafts. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 23-28.	0.5	0
85	Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. <i>Thrombosis and Haemostasis</i> , 2004, 92, 171-177.	1.8	24
86	Platelets and Angiogenesis in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 95-108.	1.5	282
87	Contribution of the Hemostatic System to Angiogenesis in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 5-20.	1.5	59
88	Interfering with Hemostatic System Components: Possible New Approaches to Antiangiogenic Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 145-156.	1.5	5
89	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. <i>Bone Marrow Transplantation</i> , 2004, 33, 1225-1229.	1.3	24
90	Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts. <i>Biomaterials</i> , 2004, 25, 5987-5993.	5.7	5

#	ARTICLE	IF	CITATIONS
91	Expression of Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Different Malignant Tumors.. Blood, 2004, 104, 3959-3959.	0.6	1
92	Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues.. Blood, 2004, 104, 3958-3958.	0.6	13
93	Occurrence of Components of Fibrinolytic Pathways in Situ in Laryngeal Cancer. Seminars in Thrombosis and Hemostasis, 2003, 29, 317-320.	1.5	7
94	Tissue Factor-Dependent Coagulation Activation and Impaired Fibrinolysis in Situ in Gastric Cancer. Seminars in Thrombosis and Hemostasis, 2003, 29, 291-300.	1.5	49
95	Coagulation activators and inhibitors in the neointima of polyester vascular grafts. Blood Coagulation and Fibrinolysis, 2003, 14, 433-439.	0.5	9
96	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis, 2003, 90, 140-146.	1.8	41
97	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis, 2003, 90, 140-6.	1.8	21
98	The Hemostatic System and Angiogenesis in Malignancy. Neoplasia, 2001, 3, 371-384.	2.3	108
99	Lactacystin Inhibits Cathepsin A Activity in Melanoma Cell Lines. Tumor Biology, 2001, 22, 211-215.	0.8	22
100	Localization of Blood Coagulation Factors In Situ in Pancreatic Carcinoma. Thrombosis and Haemostasis, 2001, 86, 1416-1420.	1.8	42
101	Cathepsin A activity in primary and metastatic human melanocytic tumors. Archives of Dermatological Research, 2000, 292, 68-71.	1.1	34
102	The Effects of Polysulfonate Derivative (GL 2021) on Coagulation in Vitro and Thrombosis in Vivo. Thrombosis Research, 2000, 99, 99-104.	0.8	1
103	Platelet activation and its role in thrombin generation in platelet-induced thrombin generation time. Thrombosis Research, 2000, 100, 419-426.	0.8	10
104	Expression of Prothrombin Fragment 1+2 in Cancer Tissue as an Indicator of Local Activation of Blood Coagulation. Thrombosis Research, 2000, 97, 335-342.	0.8	33
105	Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in situ in Laryngeal Carcinoma. Thrombosis and Haemostasis, 1999, 82, 1659-1662.	1.8	28
106	Platelet-Induced Thrombin Generation Time II (PITT II) A Modified Global Coagulation Test to Monitor Prophylactic Anticoagulation with Vitamin K Antagonists?. Thrombosis Research, 1999, 96, 77-81.	0.8	3
107	Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC). European Journal of Cancer, 1999, 35, S317.	1.3	3
108	Von Willebrand factor antigen and fibronectin in essential hypertension. Thrombosis Research, 1995, 79, 331-336.	0.8	14

#	ARTICLE	IF	CITATIONS
109	Thrombin increases the metastatic potential of tumor cells. <i>International Journal of Cancer</i> , 1993, 54, 793-806.	2.3	109
110	Protein c and protein S in patients with peripheral arterial occlusive disease. <i>Thrombosis Research</i> , 1993, 70, 489-492.	0.8	0
111	Decreased plasma protein C levels after high dosage of acetylsalicylic acid. <i>Thrombosis Research</i> , 1993, 69, 401-406.	0.8	1
112	Pathways of Coagulation/Fibrinolysis Activation in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 1992, 18, 104-116.	1.5	168
113	Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 429-437.	0.5	57
114	Thrombin enhances tumor cell adhesive and metastatic properties via increased α IIb β 3 expression on the cell surface. <i>Thrombosis Research</i> , 1992, 68, 233-245.	0.8	71
115	Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. <i>Cancer</i> , 1991, 67, 1377-1383.	2.0	40
116	Malignant Melanoma: Interaction with Coagulation and Fibrinolysis Pathways In Situ. <i>American Journal of Clinical Pathology</i> , 1990, 93, 516-521.	0.4	58
117	Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. <i>Cancer</i> , 1990, 65, 481-485.	2.0	72
118	Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. <i>Thrombosis Research</i> , 1989, 55, 279-284.	0.8	21
119	Indirect Activation of Blood Coagulation in Colon Cancer. <i>Thrombosis and Haemostasis</i> , 1989, 62, 1062-1066.	1.8	46
120	Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. <i>Thrombosis Research</i> , 1988, 51, 575-581.	0.8	27
121	XYY syndrome and acute myeloblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1987, 24, 363-365.	1.0	15
122	Plasma Factor XIII and some other Haemostasis Parameters in Patients with Diabetic Angiopathy. <i>Acta Haematologica</i> , 1986, 76, 81-85.	0.7	23